Weill Medical College of Cornell University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Weill Medical College of Cornell University sits in the top decile of US sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count).
Weill Medical College of Cornell University: 701 sponsored US clinical trials, 127 recruiting.
Weill Medical College of Cornell University sponsors 701 registered US clinical trials on ClinicalTrials.gov, 127 of them currently recruiting, and 387 completed. 89 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 20 trials.
Top-decile sponsor footprint
Weill Medical College of Cornell University ranks in the top decile of sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
387 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
701 total, page 3 of 15
Liver Transplantation for Unresectable Liver Limited Colorectal Metastases
NCT04742621
Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT04542161
Tissue Collection for Drug Screening and Bioanalysis
NCT04852354
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT04371913
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
NCT04402151
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT03804944
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
NCT03803332
Use of Artificial Intelligence for Clinical Assessment of Assisted Reproductive Techniques and IVF Outcomes
NCT04255615
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
NCT04190862
Selective Laryngeal Reinnervation for Bilateral Vocal Fold Paralysis
NCT03980275
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
NCT04081701
Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction
NCT06096688
Oral Iron in Children With Chronic Kidney Disease
NCT03991169
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT03449238
Virtual Reality for Pain Management in Burn Patients
NCT04685486
Ablative Therapy in the Management of Prostate Cancer
NCT03492424
Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions
NCT03218137
Endoscopic Bariatric Therapies (EBTs): A Retrospective and Prospective Multicenter Registry
NCT04494048
Quantifying New Heart Muscle Cells
NCT06587165
Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)
NCT02316314
Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis
NCT03256240
Sex Selection of Human Spermatozoa
NCT05500573
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
NCT01776398
Changes Associated With H. Pylori and Gastric Carcinogenesis
NCT02164409
Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals
NCT02455479
Gamete Treatment to Correct Fertilization Failure
NCT01944332
Cryopreservation of Ovarian Tissue
NCT01558544
A Technology-based Psychosocial Intervention to Support Social Engagement and Well-being in Older Adults With HIV
NCT06560970
Developing a Communication Intervention for People With Memory Challenges and Their Care Partners
NCT05143255
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab
NCT05650723
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
NCT04994977
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
NCT05731791
Combination Immunotherapy in Colorectal Cancer
NCT05571293
Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer
NCT05471414
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
NCT05382208
Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
NCT05345444
Moving Well for Total Knee Arthroplasty (TKA)
NCT05217420
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
NCT04984343
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
NCT04302324
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04946370
Delirium in Children Undergoing Stem Cell Transplantation
NCT04937400
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
NCT04270175
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy
NCT04937062
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
NCT03649724
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
NCT04395222
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks
NCT04422132
Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC
NCT04506567
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
NCT04175210
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
NCT03863184
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)
NCT04021108
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 111 |
| Phase 3 | 26 |
| Phase 4 | 63 |
Therapeutic Areas
What is open in the Weill Medical College of Cornell University pipeline
127 recruiting of 701 indexed (18% open); 387 completed (55%).
Phase mix: 89 late (III/IV) vs 197 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Weill Medical College of Cornell University: open-pipeline peers nationwide
Peers matched on 701 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 701 trials (± recruiting share)
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- Sanofi · 713 trials · 10% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
- University of Miami · 721 trials · 20% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Children's Hospital of Philadelphia · 18% recruiting · 431 trials
- University of California, Berkeley · 18% recruiting · 72 trials
- Burke Medical Research Institute · 18% recruiting · 11 trials
- Grand Valley State University · 18% recruiting · 11 trials
Related
What to do with this Weill Medical College of Cornell University page
701 registered trials is a research-attention snapshot, not an endorsement of Weill Medical College of Cornell University or any single study.
- 127 of Weill Medical College of Cornell University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Weill Medical College of Cornell University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Weill Medical College of Cornell University pipeline card: 701 registered trials from official public datasets.Report a data error.